Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q12w | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q8w | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Placebo IV, Drug: Ustekinumab 90 mg SC q8w | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Placebo SC, Drug: Ustekinumab 130 mg IV, Drug: Ustekinumab 90 mg SC q12w | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): 001, 005, 006 | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q8w; Assigned to Arm(s): 003, 004 | Intervention Type: DRUG; Name: Ustekinumab 130 mg IV; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q12w; Assigned to Arm(s): 002, 005
B: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
C: Arm Label: Placebo (IP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (IP) | Arm Label: Ustekinumab 1mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 1mg/kg (IP) | Arm Label: Ustekinumab 3 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 3 mg/kg (IP) | Arm Label: Ustekinumab 6 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 6 mg/kg (IP) | Arm Label: Placebo IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Responder - Placebo SC (MP) | Arm Label: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP) | Arm Label: Ustekinumab IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Responder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Placebo (IP); Assigned to Arm(s): Placebo (IP) | Intervention Type: DRUG; Name: Ustekinumab 1mg/kg (IP); Assigned to Arm(s): Ustekinumab 1mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 3 mg/kg (IP); Assigned to Arm(s): Ustekinumab 3 mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 6 mg/kg (IP); Assigned to Arm(s): Ustekinumab 6 mg/kg (IP) | Intervention Type: DRUG; Name: Placebo IV - Responder - Placebo SC (MP); Assigned to Arm(s): Placebo IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP); Assigned to Arm(s): Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
D: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): 001

Answer: B